C I Civin

Summary

Publications

  1. ncbi request reprint Highly purified CD34-positive cells reconstitute hematopoiesis
    C I Civin
    Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 14:2224-33. 1996
  2. ncbi request reprint Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors
    S D Gore
    Johns Hopkins Oncology Center, Baltimore, MD 21287 8963, USA
    Exp Hematol 23:413-21. 1995
  3. ncbi request reprint High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector
    Z Gao
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Stem Cells 19:247-59. 2001
  4. ncbi request reprint The adapter protein CrkL associates with CD34
    D M Felschow
    Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD, USA
    Blood 97:3768-75. 2001
  5. ncbi request reprint JAK3: expression and mapping to chromosome 19p12-13.1
    M G Safford
    Oncology Center, Department of Biology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Exp Hematol 25:374-86. 1997
  6. ncbi request reprint SZF1: a novel KRAB-zinc finger gene expressed in CD34+ stem/progenitor cells
    C Liu
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 5001, USA
    Exp Hematol 27:313-25. 1999
  7. ncbi request reprint CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors
    J D'Costa
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Leukemia 19:921-9. 2005
  8. ncbi request reprint Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations
    Z Gao
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Hematol 29:910-21. 2001
  9. ncbi request reprint Human AML cells in NOD/SCID mice: engraftment potential and gene expression
    R Lumkul
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Leukemia 16:1818-26. 2002
  10. ncbi request reprint Comparisons of alloreactive potential of clinical hematopoietic grafts
    W Leung
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 5001, USA
    Transplantation 68:628-35. 1999

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Highly purified CD34-positive cells reconstitute hematopoiesis
    C I Civin
    Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 14:2224-33. 1996
    ..In particular, we wanted to determine if the CD34+ marrow cell grafts generated hematopoietic reconstitution, since a positive result would motivate further development and use of this methodology...
  2. ncbi request reprint Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors
    S D Gore
    Johns Hopkins Oncology Center, Baltimore, MD 21287 8963, USA
    Exp Hematol 23:413-21. 1995
    ..Thus, while the effects of SF are most marked in combination with other growth factors, SF appears to bind to and directly maintain the active cell-cycle characteristics of isolated CD34+ cells...
  3. ncbi request reprint High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector
    Z Gao
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Stem Cells 19:247-59. 2001
    ..This study provides evidence that lentiviral vectors transduced both short-term and long-term engrafting human cells, and mediated persistent transgene expression at high levels in multiple lineages of hematopoietic cells...
  4. ncbi request reprint The adapter protein CrkL associates with CD34
    D M Felschow
    Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD, USA
    Blood 97:3768-75. 2001
    ..Our investigations shed new light on signaling pathways of CD34 by demonstrating that CD34 couples to the hematopoietic adapter protein CrkL. (Blood. 2001;97:3768-3775)..
  5. ncbi request reprint JAK3: expression and mapping to chromosome 19p12-13.1
    M G Safford
    Oncology Center, Department of Biology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Exp Hematol 25:374-86. 1997
    ..Using fluorescence in situ hybridization we have localized JAK3 to 19p12-13.1, the same region of chromosome 19 to which the LEY I-L hormone maps (19p12-13.2)...
  6. ncbi request reprint SZF1: a novel KRAB-zinc finger gene expressed in CD34+ stem/progenitor cells
    C Liu
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 5001, USA
    Exp Hematol 27:313-25. 1999
    ..The expression pattern of SZF1 transcripts and the transcriptional repression of a CD34+-specific promoter demonstrate a possible role for SZF1 in hematopoietic stem/progenitor cell differentiation...
  7. ncbi request reprint CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors
    J D'Costa
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Leukemia 19:921-9. 2005
    ..These findings support the development of therapeutics that target the ability of CBFbeta-SMMHC to interact with AML1 or to multimerize via its assembly competence domain...
  8. ncbi request reprint Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations
    Z Gao
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Exp Hematol 29:910-21. 2001
    ..Hematopoiesis derived from actual CD34(-) cells is difficult to distinguish from that due to CD34(+) cells potentially contaminating the preparations...
  9. ncbi request reprint Human AML cells in NOD/SCID mice: engraftment potential and gene expression
    R Lumkul
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Leukemia 16:1818-26. 2002
    ....
  10. ncbi request reprint Comparisons of alloreactive potential of clinical hematopoietic grafts
    W Leung
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 5001, USA
    Transplantation 68:628-35. 1999
    ..We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients...
  11. ncbi request reprint Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
    K F Tse
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD, USA
    Leukemia 15:1001-10. 2001
    ..The activity against FLT3 suggests a potential therapeutic application for AG1296 or similar drugs in the treatment of leukemias involving deregulated FLT3 tyrosine kinase activity and as a tool for studying the biology of FLT3...
  12. ncbi request reprint Characterization of the tyrosine kinase Tnk1 and its binding with phospholipase C-gamma1
    D M Felschow
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Biochem Biophys Res Commun 273:294-301. 2000
    ..Conversely, GST-Tnk1(PR) protein constructs complexed with endogenously expressed PLC-gamma1. The association of Tnk1 with PLC-gamma1 suggests a role for Tnk1 in phospholipid signal transduction...
  13. pmc High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias
    S Morisot
    Department of Pediatrics, Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Leukemia 24:1859-66. 2010
    ..This very high frequency of LSCs suggests that a hierarchical LSC model is not valuable for poor-outcome ALL...
  14. ncbi request reprint Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production
    L D Lewis
    Department of Medicine and Pharmacology and Molecular Sciences Division of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Hum Exp Toxicol 23:173-85. 2004
    ..These findings support the hypothesis that mtDNA is one of the intracellular targets involved in the pathogenesis of AZT-associated bone marrow progenitor cell toxicity...
  15. pmc Mice deficient in MIM expression are predisposed to lymphomagenesis
    D Yu
    Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Oncogene 31:3561-8. 2012
    ....
  16. ncbi request reprint Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia
    D M Loeb
    Division of Pediatric Oncology, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Med Pediatr Oncol 37:365-71. 2001
    ..Ten had grade 3 or 4 GI toxicity. One patient died of sepsis. CONCLUSIONS: HDAC administered as a part of timed sequential therapy yields an excellent remission induction rate with manageable toxicity...
  17. ncbi request reprint Identification of a region on the outer surface of the CBFbeta-SMMHC myeloid oncoprotein assembly competence domain critical for multimerization
    L Zhang
    Divisions of Pediatric Oncology and Immunology and Hematopoiesis, Johns Hopkins University, Baltimore, MD 21231, USA
    Oncogene 25:7289-96. 2006
    ..Each helix mutant retained the ability to bind the mSin3A corepressor. Agents interacting with the outer surface of the CBFbeta-SMMHC ACD that prevent multimerization may be effective as novel therapeutics in AML...
  18. ncbi request reprint Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin
    C L Schwartz
    Division of Pediatric Oncology, Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore
    J Clin Oncol 5:1900-11. 1987
    ..These results provide the basis for a clinical trial of bone marrow transplantation using combined pharmacologic/immunologic purging of T lymphoblasts from patients' harvested autologous marrow...
  19. ncbi request reprint Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells
    G T Hoehn
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 5001, USA
    Oncogene 12:903-13. 1996
    ..1), near the p53 locus. Thus, Tnk1 is a novel tyrosine kinase that may be involved in signalling pathways utilized broadly during fetal development, more selectively in adult tissues and in cell of the lymphohematopoietic system...